当前位置:首页 - 行情中心 - 瑞普生物(300119) - 财务分析 - 现金流量表

瑞普生物

(300119)

  

流通市值:55.08亿  总市值:75.62亿
流通股本:3.39亿   总股本:4.65亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,610,631,859.391,621,456,169.29748,563,081.113,420,890,570.73
  收到的税费返还6,007,934.294,660,283.371,794,143.565,003,379.63
  收到其他与经营活动有关的现金92,257,718.2956,093,528.4711,244,87377,931,842.16
  经营活动现金流入小计2,708,897,511.971,682,209,981.13761,602,097.673,503,825,792.52
  购买商品、接受劳务支付的现金1,431,083,859.82901,529,380.36461,322,813.41,875,217,866.96
  支付给职工以及为职工支付的现金405,935,479.26257,529,799.38139,289,062.32511,182,431.06
  支付的各项税费177,979,803.49118,735,742.6551,262,720.06164,256,998.13
  支付其他与经营活动有关的现金315,942,904.26210,770,965.3998,377,975.36655,634,877.97
  经营活动现金流出小计2,330,942,046.831,488,565,887.78750,252,571.143,206,292,174.12
  经营活动产生的现金流量净额377,955,465.14193,644,093.3511,349,526.53297,533,618.4
二、投资活动产生的现金流量:
  收回投资收到的现金1,695,583,569913,132,056485,712,4832,739,125,076.16
  取得投资收益收到的现金42,030,659.9810,160,206.652,646,592.7582,686,982.45
  处置固定资产、无形资产和其他长期资产收回的现金净额88,082.4785,542.4761,043.66276,375.45
  处置子公司及其他营业单位收到的现金净额---92,457,782.98
  收到的其他与投资活动有关的现金140,000--616,205.49
  投资活动现金流入小计1,737,842,311.45923,377,805.12488,420,119.412,915,162,422.53
  购建固定资产、无形资产和其他长期资产支付的现金203,660,527.497,190,768.7349,547,182.27176,103,686.05
  投资支付的现金1,953,589,6241,038,659,624592,099,6242,466,284,306
  取得子公司及其他营业单位支付的现金7,970,520.845,100,000-170,550,000
  投资活动现金流出小计2,165,220,672.241,140,950,392.73641,646,806.272,812,937,992.05
  投资活动产生的现金流量净额-427,378,360.79-217,572,587.61-153,226,686.86102,224,430.48
三、筹资活动产生的现金流量:
  吸收投资收到的现金18,690,0007,018,000980,0001,130,000
  其中:子公司吸收少数股东投资收到的现金10,890,0007,018,000980,0001,130,000
  取得借款收到的现金1,127,672,140.03825,168,155.57173,517,061.651,186,430,465.2
  收到其他与筹资活动有关的现金1,000,0001,000,0001,001,0007,341,497.81
  筹资活动现金流入小计1,147,362,140.03833,186,155.57175,498,061.651,194,901,963.01
  偿还债务支付的现金1,000,300,013.77669,538,818.46106,457,577.61,059,436,851.2
  分配股利、利润或偿付利息支付的现金234,301,956.46215,167,779.229,226,844.17224,835,731.46
  其中:子公司支付给少数股东的股利、利润27,639,482.4818,171,690.321,731,090.6557,339,657.58
  支付其他与筹资活动有关的现金82,305,223.3722,899,483.2741,212.69161,095,521.63
  筹资活动现金流出小计1,316,907,193.6907,606,080.88116,425,634.461,445,368,104.29
  筹资活动产生的现金流量净额-169,545,053.57-74,419,925.3159,072,427.19-250,466,141.28
四、汇率变动对现金及现金等价物的影响-1,981,037.34-1,393,037.36-517,499.31-1,817.85
五、现金及现金等价物净增加额-220,948,986.56-99,741,456.93-83,322,232.45149,290,089.75
  加:期初现金及现金等价物余额625,515,953.29625,515,953.29625,515,953.29476,225,863.54
  期末现金及现金等价物余额404,566,966.73525,774,496.36542,193,720.84625,515,953.29
补充资料:
  净利润-221,915,239.8-434,469,249.03
  资产减值准备-17,759,374.71-41,434,927.25
  固定资产和投资性房地产折旧-78,369,075.71-161,951,090.15
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-78,369,075.71-161,951,090.15
  无形资产摊销-26,185,096.98-50,202,526.96
  长期待摊费用摊销-330,446.57-520,261.69
  处置固定资产、无形资产和其他长期资产的损失--2,822.84--3,819,392.15
  固定资产报废损失-60,239.52-1,295,915.14
  公允价值变动损失--10,086,942.92--75,831,147.54
  财务费用-16,058,154.9-35,416,250.71
  投资损失--6,666,382.23--34,221,849.5
  递延所得税--3,068,164.29--17,793,813.96
  其中:递延所得税资产减少--1,037,312.41--9,999,075.03
    递延所得税负债增加--2,030,851.88--7,794,738.93
  存货的减少-7,102,042.24--9,389,028.39
  经营性应收项目的减少--276,278,300.99-1,758,171.48
  经营性应付项目的增加-116,394,970.97--301,818,372.86
  其他-1,592,455.02-1,900,143.11
  现金的期末余额-525,774,496.36-625,515,953.29
  减:现金的期初余额-625,515,953.29-476,225,863.54
  现金及现金等价物的净增加额--99,741,456.93-149,290,089.75
公告日期2026-10-282026-08-262026-04-282026-03-31
审计意见(境内)标准无保留意见
TOP↑